RARE - Ultragenyx Pharmaceutical GAAP EPS of -$3.50 misses by $1.66 revenue of $90.7M misses by $5M

• Ultragenyx Pharmaceutical press release ( NASDAQ: RARE ): Q3 GAAP EPS of -$3.50 misses by $1.66 .
• Revenue of $90.7M (+11.1% Y/Y) misses by $5M .
• As of September 30, 2022, cash, cash equivalents, and marketable debt securities were $996.2 million, which includes $491.0 million in net proceeds that was received in July 2022 from OMERS through the sale of a portion of our Crysvita royalty in the profit share territory.
• Total payments to OMERS are capped at $725 million, which is 1.45 times the purchase price.
• 2022 Guidance: The Company continues to expect 2022 revenue for Crysvita in Ultragenyx territories to be between $250 million and $260 million and Dojolvi revenue to be between $55 million and $65 million.
• Shares -2.29% .

For further details see: